share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%), etc.

Altimmune | SC 13G/A：超過5%持股股東披露文件(修正)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%)等

美股sec公告 ·  02/15 01:07
牛牛AI助理已提取核心訊息
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investment entities. Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, reported their respective holdings in Altimmune's common stock. NAM reported beneficial ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares, with all shares being acquired in the ordinary course of business. The combined holdings represent a total of 3.21% of Altimmune's common stock. The filing, dated February 14, 2024, confirms that the shares were not acquired with the intention of changing or influencing the control of Altimmune Inc. The principal executive offices of Altimmune Inc. are located at 910 Clopper Road, Suite 201S, Gaithersburg, MD, United States.
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investment entities. Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, reported their respective holdings in Altimmune's common stock. NAM reported beneficial ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares, with all shares being acquired in the ordinary course of business. The combined holdings represent a total of 3.21% of Altimmune's common stock. The filing, dated February 14, 2024, confirms that the shares were not acquired with the intention of changing or influencing the control of Altimmune Inc. The principal executive offices of Altimmune Inc. are located at 910 Clopper Road, Suite 201S, Gaithersburg, MD, United States.
2023年12月31日，生物製藥公司Altimmune Inc. 成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，該文件表明重要投資實體的所有權發生了變化。總部位於特拉華州的Nuveen資產管理有限責任公司（NAM）、TIAA-CREF投資管理有限責任公司（TCIM）和Teachers Advisors, LLC（TAL）報告了各自持有的Altimmune普通股。不結盟運動報告了6,679股股票的受益所有權，TCIM報告了1,549,364股股票，TAL報告了171,273股股票，所有股份都是在正常業務過程中收購的。合併持股量共佔Altimmune普通股的3.21％。這份日期爲2024年2月14日的文件證實，收購這些股票並不是爲了改變或影響Altimmune Inc.的控制權。Altimmune Inc.的主要執行辦公室位於美國馬里蘭州蓋瑟斯堡克洛珀路910號201S套房。
2023年12月31日，生物製藥公司Altimmune Inc. 成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，該文件表明重要投資實體的所有權發生了變化。總部位於特拉華州的Nuveen資產管理有限責任公司（NAM）、TIAA-CREF投資管理有限責任公司（TCIM）和Teachers Advisors, LLC（TAL）報告了各自持有的Altimmune普通股。不結盟運動報告了6,679股股票的受益所有權，TCIM報告了1,549,364股股票，TAL報告了171,273股股票，所有股份都是在正常業務過程中收購的。合併持股量共佔Altimmune普通股的3.21％。這份日期爲2024年2月14日的文件證實，收購這些股票並不是爲了改變或影響Altimmune Inc.的控制權。Altimmune Inc.的主要執行辦公室位於美國馬里蘭州蓋瑟斯堡克洛珀路910號201S套房。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。